Clinical Trials Directory

Trials / Completed

CompletedNCT00987727

Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
82 (actual)
Sponsor
Allergan · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study will evaluate the safety and efficacy of OPTIVE® MD for ocular surface integrity in symptomatic dry eye condition in absence of obvious eye-lid inflammation.

Conditions

Interventions

TypeNameDescription
DRUGcarboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)One drop in each eye three to six times daily, as needed
DRUGsodium hyaluronate 0.18% (VISMED® Multi)One drop in each eye three to six times daily, as needed

Timeline

Start date
2009-11-01
Primary completion
2010-07-01
Completion
2010-09-01
First posted
2009-10-01
Last updated
2011-09-21
Results posted
2011-09-21

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT00987727. Inclusion in this directory is not an endorsement.

Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye (NCT00987727) · Clinical Trials Directory